Emily Lee

Dr. Emily Lee

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FYFei Yu
Fei Yu
YPYiyun Peng
Yiyun Peng
QWQi Wang
Qi Wang
YSYongying Shi
Yongying Shi
LSLonglong Si
Longlong Si
DZDemin Zhou
Demin Zhou

2 June 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RGRayudu Gopalakrishna
Rayudu Gopalakrishna
AOAndrew Oh
Andrew Oh
LHLucas Hou
Lucas Hou
ELEmily Lee
Emily Lee
JAJennifer Aguilar
Jennifer Aguilar
WMWilliam J. Mack
William J. Mack

27 February 2024 in FEBS Letters
Verified
Journal Article
Open access
RGRayudu Gopalakrishna
Rayudu Gopalakrishna
JAJennifer Aguilar
Jennifer Aguilar
AOAndrew Oh
Andrew Oh
ELEmily Lee
Emily Lee
LHLucas Hou
Lucas Hou
WMWilliam J. Mack
William J. Mack
Resveratrol prevents various neurodegenerative diseases in animal models despite reaching only low nanomolar concentrations in the brain after oral administration. In this study, based on the quenching of intrinsic tryptophan fluorescence and molecular docking, we found that trans‐resveratrol, its conjugates (glucuronide and sulfate), and dihydro‐resveratrol (intestinal microbial metabolite) bind with high affinities (Kd, 0.2–2 nm) to the peptide G palindromic sequence (near glycosaminoglycan‐binding motif) of the 67‐kDa laminin receptor (67LR). Preconditioning with low concentrations (0.01–10 nm) of these polyphenols, especially resveratrol‐glucuronide, protected neuronal cells from death induced by serum withdrawal via activation of cAMP‐mediated signaling pathways. This protection was prevented by a 67LR‐blocking antibody, suggesting a role for this cell‐surface receptor in neuroprotection by resveratrol metabolites.

25 September 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
AYAlbert Yang
Albert Yang
ELEmily Lee
Emily Lee
MBMahsa Babaei
Mahsa Babaei
PLPaul S Lee
Paul S Lee
Background/Objective: The present study is a scoping review of the literature from Medline, PubMed, and Scopus databases from 2000 to 2025. Studies were selected based on predefined criteria, including the intraoperative administration of methadone during orthopedic surgery and the reporting of outcomes such as pain scores, opioid consumption, or adverse effects. A qualitative synthesis of the findings from 13 selected studies was performed to evaluate the existing literature on the efficacy and safety of perioperative methadone for postoperative pain management in orthopedic surgery. Methods: Studies were selected based on predefined criteria, including the intraoperative administration of methadone during orthopedic surgery and the reporting of outcomes such as pain scores, opioid consumption, or adverse effects. A qualitative synthesis of the findings from 13 selected studies was performed. Results: Randomized controlled trials in adult spine surgery consistently showed that intraoperative methadone (0.2 mg/kg) significantly reduced postoperative opioid consumption by up to 50% and lowered pain scores for up to 72 h compared to other opioids. Similar benefits were observed in pediatric spine surgery, particularly with multimodal regimens including methadone, which reduced total opioid use by as much as 76%. However, for arthroscopic knee surgery, morphine provided superior analgesia compared to methadone. The safety profile of perioperative methadone appears acceptable, with no major adverse events reported when dosed appropriately. Conclusions: Perioperative methadone is an effective analgesic adjunct that reduces postoperative pain and opioid requirements, especially in major spine surgery when integrated into a multimodal strategy. Its efficacy varies by surgical context, and further high-quality research is needed to define optimal dosing and its role in other orthopedic procedures.